<DOC>
	<DOCNO>NCT02555644</DOCNO>
	<brief_summary>The main purpose study investigate safety prexasertib combination anti-cancer drug ( cisplatin cetuximab ) radiation therapy participant locally advanced head neck cancer . The study two part ( A B ) . Participants enroll one part . Participants United States may enroll either Part A Part B . Participants France may enrol Part A .</brief_summary>
	<brief_title>A Study Prexasertib ( LY2606368 ) With Chemotherapy Radiation Participants With Head Neck Cancer</brief_title>
	<detailed_description>The primary purpose Parts A B study determine recommend dose level prexasertib ( inhibitor checkpoint kinase 1 [ Chk-1 ] ) combination cisplatin radiation therapy ( Part A ) cetuximab radiation therapy ( Part B ) participant locally advanced head neck cancer .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Must able comply treatment plan followup schedule Must diagnosis head neck squamous cell carcinoma oropharynx ( tonsil , base tongue , soft palate , oropharyngeal wall ) , hypopharynx , larynx Have adequate organ function If participant reproductive potential , must agree use medically approve contraceptive precaution study three month follow last dose study drug If participant female childbearing potential , must negative serum urine pregnancy test within 14 day first dose study drug must breast feeding Must take unapproved drug treatment indication within last 28 day prior start study treatment Must receive follow prior therapy treatment : systemic therapy study cancer , radiation therapy head neck region , curativeintent surgery head neck region Have evidence distant metastatic disease Must active symptomatic fungal , bacterial viral infection , include human immunodeficiency virus ( HIV ) Hepatitis A , B , C Must serious heart condition , congestive heart failure , unstable angina pectoris , heart attack within last three month Must family history long correct QT interval ( QTc ) syndrome Must know allergic reaction component study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cancer</keyword>
</DOC>